The Bill & Melinda Gates Foundation has pledged $40 million towards advancing mRNA vaccine production in Africa and low-income countries.
The Belgian company, Quantoom Biosciences, will receive $20 million to bolster its mRNA manufacturing platform, which promises high-quality vaccines at an unprecedented speed and scale.
Additionally, two African vaccine manufacturers, the Institut Pasteur de Dakar in Senegal and Biovac in South Africa, will each receive $5 million to adopt this technology for diseases like Lassa fever, Rift valley fever, Crimean-Congo hemorrhagic fever, malaria and tuberculosis.
African public health leaders, including Nigeria’s Dr. Muhammad Ali Pate and Dr. Amadou Sall, have lauded the initiative, emphasizing the importance of Africa being able to produce its own vaccines in times of need. The plan has also gained positive coverage from mainstream media outlets and has been welcomed as a significant stride towards global health.
However, some medical experts and critics have raised concerns about the safety and efficacy of mRNA vaccines. Dr. Pierre Kory and Dr. Meryl Nass, members of the Front Line COVID-19 Critical Care Alliance, argue that the mRNA vaccine platform poses unique risks and may lead to unintended consequences, such as blood clots, heart attacks, strokes, myocarditis, and cancers. They emphasize that the platform’s purity and potency cannot be assured, which raises serious safety concerns.
Dr. Peter McCullough further asserts that mRNA vaccines have shown inherent flaws, with millions of reported injuries and thousands of deaths associated with the mRNA COVID-19 vaccines. He points to the unprecedented spike in adverse events as a strong warning against expanding the use of this technology. Additionally, the presence of undisclosed components and DNA plasmids in the vaccines poses a risk of mutations and cancers, according to Dr. Nass.